Arcturus Therapeutics ARCT 0.0% announced this morning that it has initiated dosing of its Covid-19 vaccine candidate—LUNAR COV-19, (ARCT-021)—in a Phase 1/2 study in collaboration with Duke ...

Arcturus Therapeutics is currently developing a second gene therapy utilising its LUNAR lipid nanoparticles and self-amplifying mRNA, which targets OTCD. The treatment has been named ARCT-810 or ...

--Arcturus Therapeutics, a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today ...

Arcturus Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call Thursday, March 6, 2025 @4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS ...

Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson ...

Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics.

From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey Nov. 17, 2023 3:01 AM ET Arcturus Therapeutics Holdings Inc. (ARCT) Stock ARCT 2 Comments 2 Likes Nelson Alves ...

Arcturus Therapeutics First Quarter 2025 Earnings Conference Call Monday, May 12, 2025 @ 4:30 p.m. ET Domestic: 1-800-267-6316 International: 1-203-518-9783 Conference ID: ARCTURUS Webcast: Link ...

Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson ...

About Arcturus Therapeutics, Inc. Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer chemistry and LUNAR ...